DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Information source: National Cancer Institute (NCI)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Refractory Plasma Cell Myeloma

Intervention: Bortezomib (Drug); Dexamethasone (Drug); Dinaciclib (Drug); Laboratory Biomarker Analysis (Other)

Phase: Phase 1

Status: Recruiting

Sponsored by: National Cancer Institute (NCI)

Official(s) and/or principal investigator(s):
Shaji Kumar, Principal Investigator, Affiliation: Mayo Clinic


This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement. Dinaciclib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dinaciclib and bortezomib together with dexamethasone may kill more cancer cells.

Clinical Details

Official title: Phase 1 Clinical Trial of a Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: MTD of dinaciclib and bortezomib when given together with dexamethasone, based on the incidence of dose-limiting toxicity (DLT), graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

Secondary outcome:

Incidence of adverse events, graded according to NCT CTCAE version 4.0

Overall response rate

Time to progression

Time to treatment failure

Time until hematologic nadirs (absolute neutrophil count, platelets, hemoglobin)

Detailed description: PRIMARY OBJECTIVES: I. To determine the maximally tolerated doses of dinaciclib and bortezomib, when used in combination, in two different schedules, for treatment of relapsed multiple myeloma. SECONDARY OBJECTIVES: I. To determine the toxicities associated with dinaciclib and bortezomib, when used in combination, for treatment of relapsed multiple myeloma. II. To determine the overall response rate associated with dinaciclib and bortezomib, when used in combination, for treatment of relapsed multiple myeloma. III. To explore the differences in toxicity associated with two different schedules of dinaciclib and bortezomib used in combination. TERTIARY OBJECTIVES: I. To examine if expression levels of target cyclin dependent kinase (CDK): CDK 2,5,7 and 9 levels in cluster of differentiation (CD)138-purified tumor cells, will be correlated with response (clinical and molecular) to determine if high or low level target CDK expression, if present, influences dinaciclib efficacy. II. To examine if immunoglobulin (Ig)H translocation status, P53 status and presence of v-myc myelocytomatosis viral oncogene homolog (avian) (Myc) amplification or rearrangement, determined on patient bone marrow before treatment, using a pre validated fluorescence in situ hybridization (FISH) panel to identify common myeloma translocations, will be correlated with molecular and/or clinical markers of drug activity, and to assess if specific genetic subgroups of myeloma tumors are responsive or resistant. III. To determine the gene expression profiles of myeloma cells before and after treatment to understand the role of tumor gene dysregulation and/or dinaciclib induced effects on transcription. OUTLINE: This is a dose escalation study of dinaciclib and bortezomib. Patients are assigned to 1 of 2 treatment schedules. SCHEDULE I: Patients receive dinaciclib intravenously (IV) over 2 hours and bortezomib subcutaneously (SC) on days 1, 8, and 15 and dexamethasone orally (PO) once daily (QD) on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. SCHEDULE II: Patients receive dinaciclib IV over 2 hours on day 1; bortezomib SC on days 1 and 8; and dexamethasone PO QD on days 1, 2, 8, and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and 3 months.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Serum creatinine =< 2. 5 mg/dL

- Absolute neutrophil count >= 1000/uL

- Untransfused platelet count >= 75000/uL

- Hemoglobin >= 8 g/dL

- Total bilirubin =< 1. 5 times institutional upper limit of normal (ULN)

- Patients with relapsed multiple myeloma who have already received one or more

standard treatment regimens

- Measurable disease of multiple myeloma as defined by at least ONE of the following:

- Serum monoclonal protein >= 1 g/dL

- >= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis

- Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum

immunoglobulin kappa to lambda free light chain ratio

- Monoclonal bone marrow plasmacytosis >= 30% (evaluable disease)

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

- Adequate residual organ function per treating physician discretion; Note: there is no

limit with regard to the number of prior therapies

- Provide informed written consent

- Negative pregnancy test done =< 7 days prior to registration, for women of

childbearing potential only

- Willing to provide samples for correlative research purposes

- Willing to return to consenting institution for follow-up during the study

- Recovered (i. e., =< grade 1 toxicity) from the reversible effects of prior

antineoplastic therapy Exclusion Criteria:

- Any of the following recent therapies:

- Alkylators (e. g. melphalan, cyclophosphamide) =< 14 days prior to registration

- Anthracyclines =< 14 days prior to registration

- High dose corticosteroids, immune modulatory drugs (thalidomide or

lenalidomide), or proteosome inhibitors (bortezomib) =< 7 days prior to registration

- Concomitant high dose corticosteroids (concurrent use of corticosteroids); EXCEPTION:

patients may be on chronic steroids (maximum dose 20 mg/day prednisone equivalent) if they are being given for disorders other than amyloid, i. e., adrenal insufficiency, rheumatoid arthritis, etc.

- Other active malignancy =< 2 years prior to registration; EXCEPTIONS: non-melanotic

skin cancer or carcinoma in-situ of the cervix; NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer

- Any of the following:

- Pregnant women or women of reproductive ability who are unwilling to use 2

effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of study drug

- Nursing women

- Men who are unwilling to use a condom (even if they have undergone a prior

vasectomy) while having intercourse with any woman, while taking the drug and for 30 days after stopping treatment

- Other co-morbidity which would interfere with patient's ability to participate in

trial, e. g. uncontrolled infection, uncompensated heart or lung disease

- Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered

investigational; NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment

- Peripheral neuropathy >= grade 2 on clinical examination during the screening period

- Major surgery =< 14 days prior to registration

- Currently taking strong or moderate inhibitors/inducers of cytochrome P450, family 3,

subfamily A, polypeptide 4 (CYP3A4); Note: dinaciclib is a CYP3A4 substrate; patients should not take grapefruit/grapefruit juice or St. John's wort; use of strong or moderate CYP3A4 inhibitors is prohibited from < 7 days prior to registration; use of CYP3A4 inducers is prohibited from =< 7 days prior to registration

- Any of the following conditions:

- Myocardial infarction =< 6 months prior to registration or has New York Heart

Association (NYHA) class III or IV heart failure

- Uncontrolled angina

- Severe uncontrolled ventricular arrhythmias

- Electrocardiographic evidence of acute ischemia

- Active conduction system abnormalities; NOTE: prior to study entry, any

electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant

- Known hypersensitivity to bortezomib, boron, or mannitol

- Serious medical or psychiatric illness likely to interfere with participation in this

clinical study per the judgment of the treating physician

Locations and Contacts

Mayo Clinic in Arizona, Scottsdale, Arizona 85259, United States; Recruiting
Keith Stewart, Email: stewart.keith@mayo.edu
Keith Stewart, Principal Investigator

Mayo Clinic, Rochester, Minnesota 55905, United States; Recruiting
Shaji K. Kumar, Phone: 507-284-2511, Email: kumar.shaji@mayo.edu
Shaji K. Kumar, Principal Investigator

M D Anderson Cancer Center, Houston, Texas 77030, United States; Recruiting
Sheeba K. Thomas, Phone: 713-792-3245, Email: sthomas@mdanderson.org
Sheeba K. Thomas, Principal Investigator

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia 23298, United States; Recruiting
Beata Holkova, Phone: 804-628-1939, Email: bholkova@mcvh-vcu.edu
Beata Holkova, Principal Investigator

Riverview Hospital, Wisconsin Rapids, Wisconsin 54494, United States; Recruiting
Natalie S. Callander, Phone: 877-405-6866, Email: nsc@medicine.wisc.edu
Natalie S. Callander, Principal Investigator

Additional Information

Starting date: December 2012
Last updated: June 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017